Exact Sciences to Participate in November Investor Conference
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited...
Business Wire·3h ago
More News
Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of +84.62% and +4.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16h ago
Exact Sciences Announces Third Quarter 2025 Results
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $851 million for the third quarter ended...
Business Wire·18h ago
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect
RIGL's rising Tavalisse sales, along with incremental sales from Rezlidhia and Gavreto, could power another earnings beat in the quarter to be reported.
Zacks·4d ago
Coupang Set to Report Q3 Earnings: What's in Store for the Stock?
CPNG sees momentum in Taiwan and logistics ahead of Q3 results, while investments may weigh on margins.
Zacks·4d ago
Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run?
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·4d ago
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
ZTS is poised for another earnings beat as rising demand for companion animal products like Simparica Trio and Apoquel drives expected Q3 revenue growth.
Zacks·6d ago
TEM vs. EXAS: Which Genomics Player Offers Greater Upside?
Tempus AI's soaring genomics revenues and Exact Sciences' diagnostic breakthroughs spotlight two distinct routes to precision oncology growth.
Zacks·6d ago
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter.
Zacks·7d ago
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.